Neoadjuvant immunotherapy for melanoma Review
| Authors: | Lee, A. Y.; Brady, M. S. |
| Review Title: | Neoadjuvant immunotherapy for melanoma |
| Abstract: | Clinical trials have demonstrated the efficacy of immunotherapy, especially checkpoint blockade inhibitors, in the treatment of patients with metastatic melanoma. More recently, improvements in survival have been reported in patients with high-risk resectable melanoma when these agents are used in the adjuvant setting. Increasing interest in neoadjuvant immunotherapy for high-risk resectable melanoma has been fueled by early reports of significant efficacy. We review the rationale and data behind utilizing neoadjuvant immunotherapy. © 2020 Wiley Periodicals LLC |
| Keywords: | treatment response; review; drug efficacy; comparative study; neoadjuvant therapy; cancer staging; antineoplastic agent; lymph node dissection; alpha2b interferon; cancer immunotherapy; melanoma; antineoplastic combined chemotherapy protocols; randomized controlled trials as topic; prediction; immunology; immunotherapy; immunomodulation; neoadjuvant chemotherapy; clinical trials, phase i as topic; clinical trials, phase ii as topic; neoadjuvant; programmed death 1 ligand 1; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 1 clinical trial (topic); high risk; procedures; radical resection; checkpoint blockade; resectable; immune checkpoint inhibitor; humans; human; priority journal; pembrolizumab; immune checkpoint inhibitors; administration and dosage; antineoplastic monoclonal antibody |
| Journal Title: | Journal of Surgical Oncology |
| Volume: | 123 |
| Issue: | 3 |
| ISSN: | 0022-4790 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-03-01 |
| Start Page: | 782 |
| End Page: | 788 |
| Language: | English |
| DOI: | 10.1002/jso.26229 |
| PUBMED: | 33002195 |
| PROVIDER: | scopus |
| PMCID: | PMC8366312 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 April 2021 -- Source: Scopus |
